Rohstoffaktien-Depot mit langfristansatz Strategie (Seite 4916)
eröffnet am 06.12.11 12:33:35 von
neuester Beitrag 25.03.24 15:57:57 von
neuester Beitrag 25.03.24 15:57:57 von
Beiträge: 59.636
ID: 1.170.870
ID: 1.170.870
Aufrufe heute: 29
Gesamt: 6.934.112
Gesamt: 6.934.112
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 22 Minuten | 7888 | |
| vor 14 Minuten | 5021 | |
| vor 1 Stunde | 2630 | |
| vor 1 Stunde | 2620 | |
| vor 1 Stunde | 2348 | |
| vor 19 Minuten | 2089 | |
| vor 35 Minuten | 2040 | |
| vor 34 Minuten | 1787 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.811,22 | -1,53 | 228 | |||
| 2. | 3. | 164,01 | +1,16 | 96 | |||
| 3. | 2. | 9,1800 | -4,82 | 90 | |||
| 4. | 4. | 0,1920 | -1,03 | 76 | |||
| 5. | 6. | 0,0211 | -32,59 | 53 | |||
| 6. | 34. | 0,6400 | -54,29 | 49 | |||
| 7. | 14. | 6,8040 | +0,98 | 48 | |||
| 8. | 13. | 422,80 | -14,33 | 44 |
Beitrag zu dieser Diskussion schreiben
Feedback
Die FED - Yellen - hat nicht nur Gold um 20 Uhr in den Keller geschickt, sondern auch den DOW.
Aber wahrscheinlich braucht Sie für Abnehmer ihrer (wertlosen) Anleihen, dann muss Gold in den Keller.
Gold und Silberminen gestern bis zu 10% Verlust.
Der DAX vorbörslich bei 9.200 - wahrscheinlich gibt es heute und morgen teilweise günstigere Kurse
Japan fast 2 % Minus
Australien heute morgen 1,13 % Minus - und was machen unsere Australischen Minenwerte
Altona Minig 6,4 % PLUS
Grange res. 2 % PLUS
Tiger res. 1,3 % PLus - Dochtpatt unten - charts kommen später - sehenswert.
und der Goldwert Silverlake - 2 cent Minus - 5,3 % Minus - die Unterstützung getestet.
Bei Australien ist -wahrscheinlich- das meiste der Korrektur vorbei - evtl. am Freitag
Japan - will evtl. nur ein -W- machen oder die starke Unterstützung gleich darunter testen
Der S&P500 - hat um 20 Uhr mit dem Docht die Unterstützung getestet und dann wieder nach oben gedreht -
Die wahrscheinlichkeit, dass es diese Woche - großer Verfall am Freitag - Seitwärts geh ist groß
Gold, nach der Übertreibung nach oben, oberhalb des Trend, ist eine Korrektur ganz normal.
Das hat man in den letzten 2 Tagen schon am Chart gesehen, die Unterstützung liegt bei 1.300 $
der gelben 200er Linie - untere Aufwärtstrendlinie. Wird die von oben getestet und dreht dann nach oben,
dann ist das das Kaufsignal - irgendwo in dem Bereich unten werden die Shorts gegrillt
Der MACD sieht auch noch nicht fertig aus, mit der Korrektur.
Kupfer sieht auch aus wie die Trendwende nach oben
Aber wahrscheinlich braucht Sie für Abnehmer ihrer (wertlosen) Anleihen, dann muss Gold in den Keller.
Gold und Silberminen gestern bis zu 10% Verlust.
Der DAX vorbörslich bei 9.200 - wahrscheinlich gibt es heute und morgen teilweise günstigere Kurse
Japan fast 2 % Minus
Australien heute morgen 1,13 % Minus - und was machen unsere Australischen Minenwerte
Altona Minig 6,4 % PLUS
Grange res. 2 % PLUS
Tiger res. 1,3 % PLus - Dochtpatt unten
- charts kommen später - sehenswert. und der Goldwert Silverlake - 2 cent Minus - 5,3 % Minus - die Unterstützung getestet.
Bei Australien ist -wahrscheinlich- das meiste der Korrektur vorbei - evtl. am Freitag
Japan - will evtl. nur ein -W- machen oder die starke Unterstützung gleich darunter testen
Der S&P500 - hat um 20 Uhr mit dem Docht die Unterstützung getestet und dann wieder nach oben gedreht -
Die wahrscheinlichkeit, dass es diese Woche - großer Verfall am Freitag - Seitwärts geh ist groß
Gold, nach der Übertreibung nach oben, oberhalb des Trend, ist eine Korrektur ganz normal.
Das hat man in den letzten 2 Tagen schon am Chart gesehen, die Unterstützung liegt bei 1.300 $
der gelben 200er Linie - untere Aufwärtstrendlinie. Wird die von oben getestet und dreht dann nach oben,
dann ist das das Kaufsignal - irgendwo in dem Bereich unten werden die Shorts gegrillt
Der MACD sieht auch noch nicht fertig aus, mit der Korrektur.
Kupfer sieht auch aus wie die Trendwende nach oben
Auf lange Sicht Silberminer, denn die Inflation wird kommen. Die schwachen Schwellenländer drehen schon, performen dieses Jahr schon zT besser als die alten Märkte. Wenn nichts dazwischen kommt. Interessante Sicht auf USA EU Ukraine:
http://www.leap2020.eu/GEAB-N-83-ist-angekommen-Umfassende-w…
http://www.leap2020.eu/GEAB-N-83-ist-angekommen-Umfassende-w…
Antwort auf Beitrag Nr.: 46.663.235 von urpferdchen am 20.03.14 07:22:45Ich bin dabei.
20k unter 0.30 € hätte ich schon noch gerne.
Oder starcore.
Die wurden gestern auch böse gerupft.
Die könnten nochmals 20% abschmieren auf 0.16 CAD.
Da bieten sich auch optimale Einstiegskurse.
20k unter 0.30 € hätte ich schon noch gerne.
Oder starcore.
Die wurden gestern auch böse gerupft.
Die könnten nochmals 20% abschmieren auf 0.16 CAD.
Da bieten sich auch optimale Einstiegskurse.
Antwort auf Beitrag Nr.: 46.663.235 von urpferdchen am 20.03.14 07:22:45Ja und der gefällt mir eben kurzfristig nicht. Mal abwarten, wie die Verfallswoche allgemein endet und was nächsten Mittwoch als Reaktion erfolgt.
Antwort auf Beitrag Nr.: 46.663.143 von prallhans am 20.03.14 06:09:14Da gibt es dann genug die Silver Lake aufsammeln. - Nicht jeden blödsinn glauben der verzapft wird.
Chart ansehen, bringt mehr.
- Nicht jeden blödsinn glauben der verzapft wird.Chart ansehen, bringt mehr.
Trading Spotlight
Wenn Gold unter 1320/1330 kommt fliegt Silver Lake raus - Australier zuerst. Hier gibt es eine Präsentation von denen:
http://www.asx.com.au/asxpdf/20140320/pdf/42nhym7zpnr45f.pdf
Bei northern iron sieht es von den Indikatoren hre so aus,als würde der Ausbruch nach unten erfolgen.
Obwohl bei Kupfer das Tagestief gestern aggressiv aufgekauft wurde. Vielleicht wird China ja nur hochgekocht? Aber die Lage dort scheint nicht so rosig zu sein.
http://www.asx.com.au/asxpdf/20140320/pdf/42nhym7zpnr45f.pdf
Bei northern iron sieht es von den Indikatoren hre so aus,als würde der Ausbruch nach unten erfolgen.
Obwohl bei Kupfer das Tagestief gestern aggressiv aufgekauft wurde. Vielleicht wird China ja nur hochgekocht? Aber die Lage dort scheint nicht so rosig zu sein.
keine Ahnubng von der Bude, aber die Biotechnologie Kundigen können sich das vielleicht auch mal näher anschauen.
IsoRay(ISR) "Explodes on Massive Volume, after Successful Treatment" -E.com - Mar 19, 2014
- J. Anderson -
www.equities.com/editors-desk/stocks/healthcare/isoray-isr-e…
"Shares in small-cap maker of radiation treatments for cancer IsoRay (ISR) exploded on Mar. 19, soaring over 80 percent on extremely high volume. The move appeared to be motivated by news that the company had used its novel Cesium-131 brachytherapy technique to treat an aggressive form of cancer in a pediatric patient.
Wild Trading Action on ISR, Despite Small Size
The news began to filter out after the opening bell, and IsoRay’s stock opened at the about same price it closed at on Tuesday. However, volume began to pick up after 10 am EST and continued gaining steam. The price peaked once at over $1.70 a share before retreating, then rallied past that level to clear $2 a share by 2 pm EST.
This resulted in the stock crashing through a rising resistance level at $1.20 that had formed in mid-August, been tested twice, and had appeared to tamp down trading action over the last few days as the stock crossed and then retreated from $1.20 a share in trading on Mar. 17. It’s possible that the size and scope of the breakout was buoyed by the stock finally breaking through this technical barrier.
Volume was incredibly high for a company of this size, with over half of the 41.5 million share float changing hands prior to 1 pm EST and movre than 20 million shares moved by 2 pm EST. The move comes less than a week after a bullish article prompted another spike in value of more than 25 percent.
A company as small as IsoRay is clearly prone to major price swings, with the shift last Friday stemming from a single internet piece being a prime example. However, IsoRay is clearly picking up steam and garnering more interest over the last few weeks. Its average daily volume prior to Wednesday had reached 3.3 percent of float, meaning shares were already turning over at a fairly rapid rate before Wednesday’s massive spike in volume.
IsoRay’s price action is also interesting in the context of the large divestment from institutional ownership over the last three months. IsoRay saw a 40 percent decline in institutional ownership over the last three months, potentially meaning that there are some extremely disappointed institutional stock-pickers out there Wednesday morning.
ISR Holds Monopoly for Novel Cesium-131 Brachytherapy Process
The reported success on Wednesday involved a pediatric patient with a recurrent metastatic Wilms tumor, a particularly aggressive cancer affecting the kidney that’s found in children. Dr. Anthony Crimaldi at the Levine Cancer Institute of Charlotte, NC reported that he was able to treat the tumor using the Cesium-131 treatment developed by IsoRay.
Brachytherapy, also known as internal radiotherapy, is a form of radiation treatment in which sources of radiation are placed in the body to give tumors high doses of isolated radiation.
“Prior to this he had been treated extensively, but nevertheless the cancer returned,” said Crimaldi. “I worked closely with IsoRay to design a custom mesh containing Cesium-131 sources and we were able to place the mesh at the time of surgery so as not to expose critical organs to high doses of radiation (lung, spinal cord, and aorta). Post-treatment dose calculations were performed confirming the delivery of dose to the resection bed and sparing of the critical structures. The patient recovered normally and has been discharged home.”
IsoRay is currently the only company using the Cesium-131 isotope for these types of treatments, potentially giving them a monopoly in the space.
"When cancers become locally advanced, they recur frequently after surgery,” said Chairman and CEO Dwight Babcock. “Radiation is therefore performed, but the amount of radiation required to successfully treat the disease is often limited with existing technologies and has the potential to increase negative side effects to the patient. With the Cesium-131 seeded mesh we can get the optimal dose to the area of concern at the time of surgery -- which we think is a real benefit for the patient."
Excitement over the potential for this form of treatment becoming used more broadly is likely creating much of the buzz surrounding IsoRay.
Crimaldi pointed out that “the process of designing the treatment mesh was done with the assistance of the IsoRay team, and was quick and simple (done with the use of cross-sectional imaging).” He continued: “The mesh was designed, manufactured, and arrived for placement in less than 1 week. This device is an option that can provide treatment in areas of prior irradiation with a dose that is highly conformal and spares normal critical structures when other treatment modalities (such as external irradiation) are not possible."
Low but Consistent Revenue, for a Tiny Company
It’s likely going to take some time for the markets to really sort things out for IsoRay. It’s not uncommon for a company with a float and market cap as small as IsoRay’s to have huge price swings following news items. However, it’s important to note that any stock that can leap this much so quickly can typically swing to the negative just as fast.
Looking past the incredible volatility of the last few months, IsoRay has posted small-but-consistent losses on small-but-consistent revenue for years. The company typically pulls in between $1 million and $1.25 million in revenue each quarter, and FY earnings since 2011 have shown a loss of $0.11 or $0.12 a share, down from a loss of $0.18 a share in 2010.
These sorts of results show a company that has yet to see the sort of action that will really define its valuation. Should the promise currently being shown by its Cesium-131 brachytherapy pan out, the company’s stock may climb even higher. However, given the tiny float, share price, and market cap, this sort of wild volatility could just as easily fizzle if the long-term value of this treatment fails to pan out. "
Gruß
P.
IsoRay(ISR) "Explodes on Massive Volume, after Successful Treatment" -E.com - Mar 19, 2014
- J. Anderson -
www.equities.com/editors-desk/stocks/healthcare/isoray-isr-e…
"Shares in small-cap maker of radiation treatments for cancer IsoRay (ISR) exploded on Mar. 19, soaring over 80 percent on extremely high volume. The move appeared to be motivated by news that the company had used its novel Cesium-131 brachytherapy technique to treat an aggressive form of cancer in a pediatric patient.
Wild Trading Action on ISR, Despite Small Size
The news began to filter out after the opening bell, and IsoRay’s stock opened at the about same price it closed at on Tuesday. However, volume began to pick up after 10 am EST and continued gaining steam. The price peaked once at over $1.70 a share before retreating, then rallied past that level to clear $2 a share by 2 pm EST.
This resulted in the stock crashing through a rising resistance level at $1.20 that had formed in mid-August, been tested twice, and had appeared to tamp down trading action over the last few days as the stock crossed and then retreated from $1.20 a share in trading on Mar. 17. It’s possible that the size and scope of the breakout was buoyed by the stock finally breaking through this technical barrier.
Volume was incredibly high for a company of this size, with over half of the 41.5 million share float changing hands prior to 1 pm EST and movre than 20 million shares moved by 2 pm EST. The move comes less than a week after a bullish article prompted another spike in value of more than 25 percent.
A company as small as IsoRay is clearly prone to major price swings, with the shift last Friday stemming from a single internet piece being a prime example. However, IsoRay is clearly picking up steam and garnering more interest over the last few weeks. Its average daily volume prior to Wednesday had reached 3.3 percent of float, meaning shares were already turning over at a fairly rapid rate before Wednesday’s massive spike in volume.
IsoRay’s price action is also interesting in the context of the large divestment from institutional ownership over the last three months. IsoRay saw a 40 percent decline in institutional ownership over the last three months, potentially meaning that there are some extremely disappointed institutional stock-pickers out there Wednesday morning.
ISR Holds Monopoly for Novel Cesium-131 Brachytherapy Process
The reported success on Wednesday involved a pediatric patient with a recurrent metastatic Wilms tumor, a particularly aggressive cancer affecting the kidney that’s found in children. Dr. Anthony Crimaldi at the Levine Cancer Institute of Charlotte, NC reported that he was able to treat the tumor using the Cesium-131 treatment developed by IsoRay.
Brachytherapy, also known as internal radiotherapy, is a form of radiation treatment in which sources of radiation are placed in the body to give tumors high doses of isolated radiation.
“Prior to this he had been treated extensively, but nevertheless the cancer returned,” said Crimaldi. “I worked closely with IsoRay to design a custom mesh containing Cesium-131 sources and we were able to place the mesh at the time of surgery so as not to expose critical organs to high doses of radiation (lung, spinal cord, and aorta). Post-treatment dose calculations were performed confirming the delivery of dose to the resection bed and sparing of the critical structures. The patient recovered normally and has been discharged home.”
IsoRay is currently the only company using the Cesium-131 isotope for these types of treatments, potentially giving them a monopoly in the space.
"When cancers become locally advanced, they recur frequently after surgery,” said Chairman and CEO Dwight Babcock. “Radiation is therefore performed, but the amount of radiation required to successfully treat the disease is often limited with existing technologies and has the potential to increase negative side effects to the patient. With the Cesium-131 seeded mesh we can get the optimal dose to the area of concern at the time of surgery -- which we think is a real benefit for the patient."
Excitement over the potential for this form of treatment becoming used more broadly is likely creating much of the buzz surrounding IsoRay.
Crimaldi pointed out that “the process of designing the treatment mesh was done with the assistance of the IsoRay team, and was quick and simple (done with the use of cross-sectional imaging).” He continued: “The mesh was designed, manufactured, and arrived for placement in less than 1 week. This device is an option that can provide treatment in areas of prior irradiation with a dose that is highly conformal and spares normal critical structures when other treatment modalities (such as external irradiation) are not possible."
Low but Consistent Revenue, for a Tiny Company
It’s likely going to take some time for the markets to really sort things out for IsoRay. It’s not uncommon for a company with a float and market cap as small as IsoRay’s to have huge price swings following news items. However, it’s important to note that any stock that can leap this much so quickly can typically swing to the negative just as fast.
Looking past the incredible volatility of the last few months, IsoRay has posted small-but-consistent losses on small-but-consistent revenue for years. The company typically pulls in between $1 million and $1.25 million in revenue each quarter, and FY earnings since 2011 have shown a loss of $0.11 or $0.12 a share, down from a loss of $0.18 a share in 2010.
These sorts of results show a company that has yet to see the sort of action that will really define its valuation. Should the promise currently being shown by its Cesium-131 brachytherapy pan out, the company’s stock may climb even higher. However, given the tiny float, share price, and market cap, this sort of wild volatility could just as easily fizzle if the long-term value of this treatment fails to pan out. "
Gruß
P.
Eine meiner Lieblingsminen Fortuna Silver hat gestern böse abgegeben. Jetzt der Gewinner im nachbörlichen Handel mit +17%.
Kann man sich bei Seeking Alpha schön per Email Alert schicken lassen so was.
Kann man sich bei Seeking Alpha schön per Email Alert schicken lassen so was.
Im Tageschart über 1 Jahr sehen Dow und besonders der Transport sauber nach Top aus heute. Yellen enttäuscht, bzw. lässt wie ihr toller Vorgänger alles im Unklaren. Wenn-dann und abwägen ohne Ende. Damit sinkt auch das Vertrauen in die US Bonds und so steigen die Zinsen und könnten einen Doppelboden bilden.
http://stockcharts.com/h-sc/ui?s=$TNX
Es wird wohl an Draghi hängen, die Schleusen zu öffnen. Timing passt. Unser Luschi-Verfassungsgericht ohne Verfassung winkt den ESM endgültig durch. Die Indizes der Peripherie und die Schrott Bonds der Griechen freuen sich.
http://stockcharts.com/h-sc/ui?s=$TNX
Es wird wohl an Draghi hängen, die Schleusen zu öffnen. Timing passt. Unser Luschi-Verfassungsgericht ohne Verfassung winkt den ESM endgültig durch. Die Indizes der Peripherie und die Schrott Bonds der Griechen freuen sich.
krass.....
Durchsuchen
